26454-53-5

Basic information

• Product Name: 9H-XANTHENE-9-CARBONYL CHLORIDE
• Synonyms: XANTHENE-9-CARBOXYLIC ACID CHLORIDE;9H-XANTHENE-9-CARBONYL CHLORIDE;9H-Xanthene-9-carbonyl chloride 97%
• CAS NO: 26454-53-5
• Molecular Formula: C₁₄H₉ClO₂
• Molecular Weight: 244.67
• Mol File: 26454-53-5.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 338.1 °C at 760 mmHg
• Flash Point: 125.3 °C
• Appearance: /
• Density: 1.335 g/cm³
• Vapor Pressure: 0.0001mmHg at 25°C
• Refractive Index: 1.625
• CAS DataBase Reference: 9H-XANTHENE-9-CARBONYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 9H-XANTHENE-9-CARBONYL CHLORIDE(26454-53-5)
• EPA Substance Registry System: 9H-XANTHENE-9-CARBONYL CHLORIDE(26454-53-5)

Safety Data

• Hazard Codes: Xi
• Statements: 36
• Safety Statements: 26
• Hazardous Substances Data: 26454-53-5(Hazardous Substances Data)

Usage

InChI:InChI=1/C14H9ClO2/c15-14(16)13-9-5-1-3-7-11(9)17-12-8-4-2-6-10(12)13/h1-8,13H

Upstream product

• 82-07-5 xanthene-9-carboxylic acid 

Downstream Products

• 6325-89-9 xanthene-9-carboxylic acid-[benzyl-(2-diethylamino-ethyl)-amide]; hydrochloride 
• 67514-17-4 3-[4-(2-methoxyphenyl)-piperazin-1-yl]-1-(xanthene-9-carbonyloxy)-propane hydrochloride 
• 1186018-80-3 (3R)-1-azabicyclo[2.2.2]oct-3-yl 9H-xanthene-9-carboxylate hydrochloride 
• 65779-16-0 3-{4-[2-(Xanthene-9-carboxamido)-ethyl]-phenyl}-propionic acid 
• 82-07-5 xanthene-9-carboxylic acid 
• 137144-28-6 9-(acetoxymesitylmethylene)xanthene 
• 72240-47-2 xanthene-9-carbaldehyde 
• 137144-23-1 9-(9-xanthenyl)-9-xanthenecarboxaldehyde 
• 137144-20-8 tert-butyl 9-xanthenyl ketone 
• 137144-24-2 di-9-xanthenyl ketone 
• 137144-18-4 mesityl 9-xanthenyl ketone 
• 137144-19-5 2,4,6-triisopropylphenyl 9-xanthenyl ketone 
• 6325-87-7 xanthene-9-carboxylic acid-[N-(2-diethylamino-ethyl)-anilide]; hydrochloride 
• 50507-10-3 1-methyl-4-(xanthene-9-carbonyl)-piperazine 

Relevant articles and documents

Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: Identification of (3R)-3-{[hydroxy(di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2. 2.2]octane bromide (aclidinium bromide)

The objective of this work was to discover a novel, long-acting muscarinicM3 antagonist for the inhaled treatment of chronic obstructive pulmonary disease (COPD), with a potentially improved risk-benefit profile compared with current antimuscarinic agents. A series of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters were synthesized and evaluated. On the basis of its overall profile, (3R)-3-{[hydroxy(di-2-thienyl) acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide (aclidiniumbromide) emerged as a candidate for once-daily maintenance treatment of COPD. This compound is a potent muscarinic antagonist, with long duration of action in vivo, and was found to have a rapid hydrolysis in human plasma, minimizing the potential to induce class-related systemic side effects. Aclidinium bromide is currently in phase III development for maintenance treatment of patients with COPD.

Synthesis and pharmacological evaluation of phenylacetamides as sodium- channel blockers

The synthesis and structure-activity relationships of a series of phenylacetamides related to N-[3-(2,6-dimethyl-1-piperidinyl)propyl]-α- phenylbenzeneacetamide (1) (PD85639) acting at the voltage-dependent Na+ channel are described. All struct

Anti-arrhythmic azabicyclic compounds

The invention relates to new anti-arrythmic azabicyclo[3.3.1]nonanes of the general formula (I) STR1 wherein R1, R2 and R3 are C1-4 alkyl groups which are the same or different, or one of them is a benzyl group